Connect with us

archive

Pfizer 3Q Earnings Powered by Oncology, Beat Estimates

Pfizer 3Q Earnings Powered by Oncology, Beat Estimates (Reuters)

The United States’ largest drug maker, Pfizer Inc., reported that Q3 earnings beat estimates. The company earned $2.59 billion for the quarter, or 58 cents per share (excluding special items), while analysts had predicted 56 cents per share. Much of the additional profit came from a 26 percent pop in oncology drug sales, which totaled $407 million for the quarter. However, global sales for the period fell 7 percent to $12.64, due to generic competition for Lipitor and other drugs. Wall Street had expected sales of $12.7 billion. Investors in Pfizer now have to ask themselves if they can see momentum continuing at that fervid pace for oncology drugs, and if that will be enough to overcome lagging global sales. If you come up with a good answer, please let us know by commenting below.

Newsletter Signup.

Sign up to the Human Events newsletter

Advertisement
Advertisement

TRENDING NOW:

MILK-FAKE: UK Papers Push Farage Fake News 1 Day Before Election

FOREIGN AFFAIRS

Human Events from London: Farage’s Eyes Power As Brexit Party Surges.

FOREIGN AFFAIRS

Obama Judges Kill Americans’ Privacy to Help Democratic House Harass Trump

U.S. POLITICS

Extinction Rebellion’s Useful Idiots: Climate Alarmism Does Far More Harm Than Good

FOREIGN AFFAIRS

archive

Pfizer 3Q Earnings Powered by Oncology, Beat Estimates

The United Statesâ?? largest drug maker, Pfizer Inc., reported that Q3 earnings beat estimates.

Pfizer 3Q Earnings Powered by Oncology, Beat Estimates (Reuters)

The United Statesâ?? largest drug maker, Pfizer Inc., reported that Q3 earnings beat estimates. The company earned $2.59 billion for the quarter, or 58 cents per share (excluding special items), while analysts had predicted 56 cents per share. Much of the additional profit came from a 26 percent pop in oncology drug sales, which totaled $407 million for the quarter. However, global sales for the period fell 7 percent to $12.64, due to generic competition for Lipitor and other drugs. Wall Street had expected sales of $12.7 billion. Investors in Pfizer now have to ask themselves if they can see momentum continuing at that fervid pace for oncology drugs, and if that will be enough to overcome lagging global sales. If you come up with a good answer, please let us know by commenting below.

Newsletter Signup.

Sign up to the Human Events newsletter

Written By

TRENDING NOW:

MILK-FAKE: UK Papers Push Farage Fake News 1 Day Before Election

FOREIGN AFFAIRS

Human Events from London: Farage’s Eyes Power As Brexit Party Surges.

FOREIGN AFFAIRS

Obama Judges Kill Americans’ Privacy to Help Democratic House Harass Trump

U.S. POLITICS

Extinction Rebellion’s Useful Idiots: Climate Alarmism Does Far More Harm Than Good

FOREIGN AFFAIRS

Connect
Newsletter Signup.

Sign up to the Human Events newsletter